communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 77 locations in 51 countries around the world, and has approximately 14,975 employees. For more information about PAREXEL International visit www.PAREXEL.com
PAREXEL, Perceptive Informatics, LIQUENT, and HERON are registered trademarks of PAREXEL International Corporation or its affiliates.
This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.
For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limi
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1
|SOURCE PAREXEL International Corporation|
Copyright©2012 PR Newswire.
All rights reserved
. Biotech Services Take Advantage of Technological Revolution through Innovations - Research Report on Life Technologies, PerkinElmer, PAREXEL, Genomic Health, and Bio-Reference2
. PAREXEL International Announces Acquisition of HERON Group LTD, A Leading Commercialization Consultancy3
. PAREXEL International Reports Third Quarter Fiscal Year 2013 Results4
. PAREXEL Announces Date of Third Quarter Fiscal Year 2013 Earnings Release and Conference Call5
. PAREXEL International to Present at Morningstar Conference6
. PAREXEL International Reports First Quarter Fiscal Year 2013 Results7
. PAREXEL International To Present At Goldman Sachs Healthcare Conference And Jefferies Healthcare Conference8
. PAREXEL Chairman and CEO to Deliver Keynote at MassBio CRO/CMO Symposium9
. PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs10
. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts11
. PAREXEL International to Present at J.P. Morgan Healthcare Conference